Company ProfilePremium

Athena Global Technologies Limited

Company Profile Analysis

Ticker: 517429.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Athena Global Technologies Limited - Company showcase

Year Founded & Workforce

1991

65 Employees

Athena Global Technologies Limited logo

Athena Global Technologies Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Athena Global Technologies Limited Overview

Athena Global Technologies is a Hyderabad-based micro-cap that began in 1991 as a software services and IT-education firm (VJIL Consulting) and now operates three disclosed reporting segments: offshore software services (application development, QA/testing, digital transformation, delivered mainly to US clients through its Schaumburg branch and a US subsidiary); real estate, which now drives the balance sheet; and online education through wholly owned subsidiary Tutoroot. The real estate asset is a 5-acre IT/SEZ development at Manikonda (Financial District) built under a joint development agreement with Phoenix Tech Zone. Healthcare-platform activity (MedleyMed) was restructured in March 2026. Economically, the company is now best understood as a promoter-controlled holding of a commercial real estate asset with a sub-scale software business attached. FY2024 included a ₹235.94 Cr non-cash fair-value gain on that property. Operating losses have persisted since FY2022, and debt has grown. The investment case depends on whether the property can be monetised through leasing or sale, starting with the 1,19,526 sq ft lease disclosed in September 2026.


Company's own description (FY2023-24 Annual Report, MD&A — paraphrased)

The company describes itself as a global provider of software application development, digital transformation, and QA & testing services to enterprises. The MD&A lists capabilities in:

  • AI services, such as real-time customer interaction and predictive/diagnostic applications

  • Blockchain solutions (described elsewhere by the company as built on Ethereum and Hyperledger)

  • Data science

  • IoT-based engagement solutions

  • Robotic process automation (RPA), chatbots and voicebots

  • Application development and product engineering

  • Production-environment support and QA

The MD&A also states a focus on enterprise information management, enterprise integration and data warehousing services. Client sectors named are financial services, healthcare, oil, pharmaceuticals, retail, business services, education, IT and government.

The FY2023-24 AR states that the company reports five segments on a consolidated basis:

  1. Software services

  2. Real estate

  3. Online pharmacy platform services

  4. Online trade of pharmaceutical products

  5. Online education services

The S&P/Simply Wall St description adds several service lines:

  • Digitalisation of records and OCR technology

  • Governance, risk and compliance (GRC) consulting

  • Voice and non-voice technical support

  • Business process optimisation

  • Advisory, structuring and sustainability consulting

Screener's summary (citing the FY2022-23 AR) describes the business as software development and consulting, real estate activities, and IT-enabled business support services.

Business model and revenue model

DimensionCharacterisationEvidence
Software servicesMostly time-and-material and project-based offshore/onsite services; mainly exportFX earnings were ₹817.70 lakh in FY2024 against standalone revenue of ₹970.95 lakh (about 84% export) — FY2023-24 AR
Real estateInvestment property held at fair value under Ind AS 40; income from leasing / sale of built-up spaceFY2024 investment property recognised at fair value of ₹23,900 lakh — FY2023-24 AR; lease of 1,19,526 sq ft at ₹11.19 Cr/yr from 27 Nov 2026 — BSE Reg. 30 filing, 18 Sep 2026
Online education (Tutoroot)B2C live online tutoring (subscription / course fees) for K-12 and competitive examsTutoroot launch coverage
Healthcare platforms (MedleyMed)B2B pharmacy aggregation and ERP SaaS, e-pharmacy trading, and telemedicine SaaSBusiness India feature; FY2023-24 AR
MixProduct/licensing: negligible or not disclosed. Services: dominant in operating revenue. Subscription: small (education, SaaS). Real estate rental: expected to become dominant from FY2027 if the new lease commences.Derived from the above

Value-chain position, customers and end-markets

Software services: The company acts as a small offshore delivery vendor. It sits at the bottom of the IT services value chain, as a subcontractor or niche vendor to mid-sized US enterprises. It has no disclosed platform IP of scale. Named clients are not publicly disclosed.

Real estate: The company is a land-owner and co-developer through a joint development agreement (JDA), where the developer builds and the parties share the built-up area. Its customers are office occupiers in Hyderabad's Financial District, which is a global capability centre (GCC) corridor.

Education: Customers are students and parents in India (CBSE, ICSE, IGCSE, IB curricula and IIT-JEE/NEET preparation) and, aspirationally, global markets.

Healthcare (historic): Customers were independent retail pharmacies (India has 8 lakh+ standalone medical stores, per Business India), stockists, virtual care providers, and US pharmacy businesses.

Independent characterisation

On the evidence, Athena Global is no longer primarily an IT services company. The key facts are:

  • Consolidated operating revenue has fallen from about ₹26 Cr in FY2020–21 to ₹11.2 Cr in FY2026.

  • Consolidated operating losses were recorded in each of FY2022–FY2026.

  • About ₹200–280 Cr of balance-sheet value sits in investment property.

The company's value, its debt service and its equity story now all depend on the Manikonda property. The software business is too small to cover finance costs, which were ₹17 Cr in FY2026 (Screener) against operating revenue of ₹11.2 Cr. The healthcare and ed-tech subsidiaries have been loss-making or marginal capital sinks: the investment in Medley carried at ₹3,360.94 lakh (FY2021-22 AR) was ultimately sold for ₹125.34 lakh in March 2026. Investors should analyse Athena as a leveraged real estate holding company with an option on a small tech services business, not as an IT services compounder.

Strategy

Stated strategy themes (FY2023-24 AR MD&A, paraphrased)

  • Remain a relevant, skilled and strategic partner to customers as Indian IT moderates.

  • Invest in talent development, better infrastructure, and design-thinking capabilities across the organisation.

  • Keep strategic mergers and acquisitions on the radar to add leverage to growth.

  • Grow consolidated income through the start-up subsidiaries:

    • Tutoroot, positioned as differentiated by its teaching approach.

    • MedleyMed, positioned by management as a customisable integrated pharmacy and telehealth platform with global ambitions.

  • Management states confidence in new projects but provides no quantified targets.

  • The FY2024 Schedule V disclosure attributes losses to higher manpower and administrative costs taken on in anticipation of contracts still under discussion, without matching revenue.

No investor day has been held. There are no earnings calls or investor presentations on record (0 analysts cover the stock per S&P).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeTypeTarget / scaleStatusSource
Aug 2024₹125 Cr secured listed NCD programme (refinance, repay unsecured loans, working capital)Capital structure₹125 CrSupersededEquity Bulls
Late 2024 – early 2025Proposed ₹150 Cr NCDs rated by Infomerics; about ₹40 Cr to repay debt; about ₹30 Cr interest reserveCapital structure₹150 CrWithdrawn 25 Feb 2025Infomerics PR; Reuters
1 Oct 2024MD remuneration raised to ₹96 lakh p.a.Governance / cost+₹36 lakh p.a.Approved at 32nd AGMFY2023-24 AR
25 Feb 2025Sale / lease of 1,50,000 sq ft of propertyAsset monetisation1.5 lakh sq ftPartly executed (FY2026 derecognition gain; Sep 2026 lease)Reuters
Aug 2025Conversion of 6.5 lakh promoter warrants at ₹87Equity infusionabout ₹5.66 Cr total (derived)DoneScreener
Mar–Apr 20267 lakh promoter warrants at ₹84Equity infusion₹5.88 Cr total; ₹1.47 Cr receivedAllotted 13 Apr 2026HDFC Sky
31 Mar 2026Healthcare restructuring (MedleyMed Healthcare acquisition / Medley Medical divestment)Portfolio₹10,000 / ₹1.25 CrCompletedIndiaIPO
30 May 2026Investment of up to ₹50 Cr in OCDs of Medley Medical Solutions and TutorootCapital allocation₹50 CrApproved; deployment not disclosedWhalesbook
18 Sep 20265-year lease of 1,19,526 sq ft at ₹11.19 Cr per year from 27 Nov 2026Real estate monetisationabout ₹56 Cr gross over 5 years (derived, before escalations)ContractedBSE Reg. 30
OngoingAI-led repositioning of the software brand (website titled "Custom AI Solutions & Automation Services")Brand / offeringNot quantifiedOngoingathenagt.com

Other commitments and guidance

ESG / sustainability: none disclosed. CSR is not applicable.

Cost programmes: none formally announced.

Medium-term financial targets / guidance: none disclosed.

Analytical observation: committing up to ₹50 Cr to OCDs of loss-making subsidiaries is very large relative to market capitalisation (about ₹72–75 Cr) and FY2026 equity (₹142 Cr). It would compete with debt reduction for any cash freed by property monetisation. This is the single most important capital-allocation decision to monitor.

Products & Services

Pricing models are not publicly disclosed for any line unless stated.

Software Services segment

OfferingDescription / capabilitiesTarget customerLaunch / latest yearFlagship / namedSource
Software application developmentCustom application builds and re-engineering; offshore/onsite model through the Hyderabad EOU and US branchMid-size enterprises, mainly USCore since 1990s; currentNone namedFY2023-24 AR MD&A
Product engineeringBuilding "future-proof" products for clientsISVs, enterprisesCurrent—FY2023-24 AR
QA & testingFunctional/production QA; "custodian of your production environment" positioningEnterprisesCurrent—FY2023-24 AR
Digital transformationCloud, analytics, process digitisationEnterprisesCurrent—AR; LinkedIn
AI servicesReal-time customer interaction, predictive and diagnostic applicationsEnterprisesCurrent—AR
Blockchain"Internet of Value" solutions on Ethereum and HyperledgerEnterprisesCurrent—AR; LinkedIn
Data science / analyticsModel design and actionable intelligenceEnterprisesCurrent—AR
IoT solutionsCustomer engagement through connected devicesEnterprisesCurrent—AR
RPA, chatbots and voicebotsBusiness process automation powered by cognitive technologiesEnterprisesCurrent—AR
Enterprise information management / integration / data warehousingEIM, EAI and DW servicesEnterprisesCurrent—AR (Opportunities section)
Digitalisation of records / OCRDocument digitisation and OCREnterprises, governmentCurrent—S&P profile
GRC consultingGovernance, risk and compliance advisoryEnterprisesCurrent—S&P profile
Voice / non-voice technical supportIT-enabled support (ITES)EnterprisesCurrent—S&P; Screener
Business process optimisationProcess consultingEnterprisesCurrent—S&P profile
Advisory, structuring, sustainability consultingConsultingCorporatesCurrent—S&P profile
Legacy branded productsVJ STS, VJPDS (domestic installations, mid-1990s)Indian corporates1995-96VJ STS, VJPDSIIFL summary
Legacy education servicesIT training centres (9 by FY1996)Students1990s; discontinued (presumed)—IIFL summary

Real Estate segment

Asset / offeringDescriptionSize / valueStatusSource
Manikonda Financial District IT/SEZ development5 acres at Sy. No. 203 (part), Manikonda Jagir, Rajendra Nagar Mandal, Ranga Reddy District; developed through a JDA with Phoenix Tech Zone Pvt LtdCompany's share of buildings fair-valued at ₹23,900 lakh (FY2024)Completion approval received FY2024FY2023-24 AR
Sale/lease programmeBoard approval to sell/lease 1,50,000 sq ft1,50,000 sq ftApproved 25 Feb 2025Reuters
Partial derecognitionPortion of investment property derecognised, gain ₹23.40 Cr—Q3 FY2026FY2026 results coverage
Lease contract1,19,526 sq ft leased for 5 years at ₹11.19 Cr per year (about ₹78 per sq ft per month, derived)1,19,526 sq ftCommences 27 Nov 2026BSE Reg. 30, 18 Sep 2026

Online Education segment (Tutoroot Technologies)

OfferingDescriptionTarget customerYearSource
"LEARN" platformIn-house platform with live interactive classes, live simulations, adaptive assessments, subject demo videos and coursewareK-12 and exam aspirantsLaunched about 2021 (company founded 2019)Business News Today; Glassdoor
Personalised tuitions1:1 and small-group live online tutoring with part-time faculty (e.g., CBSE computer science)CBSE / ICSE / IGCSE / IB studentsCurrentGlassdoor job listing
Competitive exam preparationIIT-JEE and NEET programmesGrade 11–12 studentsCurrentLaunch coverage
Classroom teachingHybrid / classroom programmesStudentsCurrentGlassdoor

Healthcare platforms (MedleyMed — restructured March 2026)

OfferingDescriptionTarget customerYearSource
B2B pharmacy aggregation / replenishmentAggregator for thousands of small pharmacies; claimed 95–98%+ fulfilment backed by its backend network; loyalty rewardsIndependent pharmacies (India)c. 2017–2021Business India feature
Pharmacy franchise modelFranchise network under the MedleyMed brandPharmacy entrepreneursAnnounced 2021BioSpectrum
Pharmacy ERP (SaaS)Backend ERP for pharmacy operations, inventory and contractingPharmaciesCurrent at the timeBusiness India; YourStory
Telemedicine SaaS / virtual clinicOnline consultation, diagnostics, built-in EHR, digital prescribingVirtual care providers, patients2,021YourStory; BioSpectrum
Local street clinicsPhysical clinics building on the platformPatientsc. 2022Business India
US digital health suitePlatform solutions for US pharmacy and virtual-care businesses (offices in Hyderabad and Austin, Texas)US pharmacies, virtual care companiesSep 2021BioSpectrum; YourStory
Online trade of pharma productsTrading of pharmaceutical products (segment 4)Pharmacies / consumersFY2023–FY2025FY2023-24 AR; IndiaIPO

It does not sit easily with Medley's FY2025 revenue of ₹2.71 lakh.

Financial Narrative

Sources: Screener (C-MOTS), StockAnalysis (S&P), Business Standard / Capital Market, ARs as cited. Figures are rounded to ₹ Cr. FY2026 includes the ₹32.36 Cr exceptional loss on the Medley divestment and a ₹23.40 Cr property gain in other income.

Income statement (₹ Cr)

Notes:

  • FY2025 PBT of ₹(1,922.64) lakh is from the FY2024-25 Directors' Report.

  • FY2026 PBT is the sum of reported quarterly PBT: -4.35 (Q1), -6.50 (Q2), 9.32 (Q3), -37.20 (Q4).

  • FY2026 reported diluted EPS is not captured in sources reviewed; the derived figure assumes 14.05m shares to Aug 2025 and 14.70m thereafter.

  • Screener shows FY2026 PAT of -13 because it excludes the exceptional item. The reported consolidated loss of ₹45.68 Cr (₹4,567.62 lakh) is confirmed by ScanX and Whalesbook coverage of the 30 May 2026 results.

  • Diluted EPS for earlier years is the same as basic or is not separately disclosed.

  • The company has never declared a dividend since inception (FY2023-24 AR).

Margin profile (%)

Revenue CAGR FY2022–FY2026 (derived): -13.6% per year. Screener reports a 5-year sales CAGR of -16% and a 3-year CAGR of -2%.

Commentary. The P&L has three regimes:

FY2022–FY2023 — collapse: Revenue fell from ₹20.1 Cr to ₹12.0 Cr. Expense levels held at ₹27–28 Cr as the company kept funding Medley and Tutoroot build-outs, pushing operating losses to ₹15 Cr.

FY2024 — accounting windfall: Completion of the Manikonda JDA allowed the company to recognise the buildings at fair value. This added ₹235.94 Cr to other income and turned a structurally loss-making year into a ₹205 Cr profit. The gain was non-cash and is not repeatable. Note also the FY2024 Q4 expense spike (₹16.93 Cr in the quarter vs ₹4–7 Cr run-rate), which management did not explain in available extracts.

  • FY2025–FY2026 — reversion to losses, now with higher finance costs. FY2025 showed some operating discipline (OPM -46%, Q3 FY2025 near break-even at -0.72%). FY2026 regressed: revenue fell 28% and Q3 FY2026 expenses jumped to ₹8.93 Cr. Marketsmojo reports employee cost at 82.65% of revenue in Q4 FY2026. Finance costs reached ₹17 Cr, more than the entire revenue base.

Quarterly trend (₹ Cr, consolidated)

Sources: Screener quarterly table; Q4 FY2026 PBT and net profit (including exceptional item) from Marketsmojo / Kotak Neo / Whalesbook; Q1 FY2027 from Capital Market (JM Financial), 15 Aug 2026.

Q1 FY2027 is the best operating quarter in two years. Sales rose 57% YoY to ₹4.75 Cr and the operating margin was close to break-even (-0.84% vs -46.03%). This is an early sign that the cost base has been reset.

Balance sheet (₹ Cr, consolidated, 31 March)

Notes:

  • Infomerics cites total debt of about ₹85.39 Cr at 31 March 2024, consistent with Screener's ₹86 Cr.

  • Net debt approximately equals gross debt; given small annual net cash flows (FY2026 net cash flow +₹9 Cr), cash is likely in single-digit ₹ Cr (inference).

  • Working capital is negative on Screener's working-capital-days metric (-516 days in FY2026), reflecting large other liabilities against small current assets.

Commentary.

  • The balance sheet was transformed in FY2024 when investment property moved from CWIP/land at cost to fair value. Equity went from negative ₹11 Cr to ₹200 Cr. Since then, equity has fallen through losses (₹200 Cr → ₹142 Cr in two years) while borrowings rose 51% (₹86 Cr → ₹130 Cr).

  • The fall in fixed assets in FY2026 (₹282 Cr → ₹203 Cr), the ₹23.40 Cr derecognition gain, and the +₹48 Cr investing cash flow together suggest a portion of the property was sold or transferred in FY2026. Despite that inflow, gross debt still rose by ₹30 Cr.

  • The jump in other assets to ₹66 Cr may reflect receivables from the property transaction and the Medley consideration. Screener shows debtor days of 202 in FY2026.

Cash flow (₹ Cr, consolidated)

The two data vendors disagree on FY2025 operating cash flow (₹13 Cr vs ₹9.61 Cr); both are shown. Capex as a separate line is not captured. FCF is as computed by Screener (OCF less capex).

Commentary. Positive operating cash flow in FY2024–FY2025 despite operating losses is consistent with working-capital inflows such as advances or related-party payables. The -₹57 Cr operating outflow in FY2026, against +₹48 Cr from investing, suggests the property transaction proceeds were classified in investing activities while working capital unwound (for example, settlement of liabilities, which fell from ₹62 Cr to ₹41 Cr). The -₹62 Cr FY2026 FCF was funded by ₹18 Cr of financing inflow (debt plus warrant money) and property proceeds.

Ratios (derived from the tables above unless stated)

Notes:

  • FY2023 debt-to-equity is not meaningful because equity was negative.

  • FY2026 interest coverage excludes the exceptional item; FY2024 coverage is inflated by the fair-value gain.

  • The FY2023-24 AR key-ratio disclosure reports standalone interest coverage of 20.72x for FY2024 vs -0.46x for FY2023, attributing the change to the fair-value gain.

  • Net debt/EBITDA is not meaningful because EBITDA was negative in every year.

  • The current ratio is not captured in the sources reviewed.

Interpretation.

  • Excluding the FY2024 gain, the company has not earned its interest bill in any of the last five years.

  • At FY2026 levels (₹130 Cr debt, ₹17 Cr finance cost), the implied cost of debt is about 13% (derived). This is consistent with non-bank or related-party funding: promoter and Vishwashree Enterprises loans are disclosed in FY2024 related-party transactions.

  • The new lease (₹11.19 Cr per year) would cover roughly two-thirds of the FY2026 finance cost before any operating expenses. That illustrates both its importance and its insufficiency on its own.

Standalone summary (₹ Cr)

Sources: FY2021-22, FY2023-24 and FY2024-25 ARs; Whalesbook / ScanX for FY2026. FY2026 standalone other income and PBT are not captured. Q3 FY2026 standalone profit was ₹348.36 lakh on revenue of ₹223.76 lakh (ScanX).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipCountryBusinessStatus / notesSource

Athena Global Technologies Ltd

Listed parent

India

Software services; real estate (investment property)

BSE 517429

AR

Tutoroot Technologies Pvt Ltd

Wholly owned subsidiary

India

Online education

Investment ₹1,457.80 lakh (FY2022 AR); FY2024 turnover ₹36.01 lakh, PBT ₹4.11 lakh (AOC-1)

FY2021-22 AR; FY2023-24 AR

Athena Global Technologies, Inc.

Wholly owned subsidiary

USA

Software services / onsite delivery

FY2024 AOC-1: turnover 354.01, PBT 48.52 (reported in the USD-entity column; unit presentation in the AR is ambiguous)

FY2023-24 AR

Athena Global Technologies UK Ltd

Wholly owned subsidiary

UK

Software development

Incorporated 30 May 2024; "yet to commence operations" per FY2024 AOC-1

BSE filing; FY2023-24 AR

MedleyMed Healthcare Solutions Pvt Ltd (CIN U24239TG2019PTC136763)

100% acquired 31 Mar 2026 for ₹10,000 (previously a step-down subsidiary through Medley)

India

Healthcare / pharma trading

Turnover ₹299.95 lakh (FY23), ₹299.75 lakh (FY24), ₹44.18 lakh (FY25)

IndiaIPO

Medley Medical Solutions Pvt Ltd

Former subsidiary; entire stake divested 31 Mar 2026 to MedleyMed Healthcare Solutions for ₹1,25,33,689

India

Pharmacy platform, telemedicine

FY2024 turnover ₹92.37 lakh, PBT ₹(374.16) lakh (AOC-1)

IndiaIPO; FY2023-24 AR

MedleyMed Logistics Pvt Ltd

Step-down subsidiary (FY2024)

India

Logistics for MedleyMed

Current status not disclosed

FY2023-24 AR (AOC-2)

Vishwashree Enterprises Pvt Ltd

Associate enterprise in which directors have substantial interest (not a subsidiary)

India

Related-party lender

Loans received ₹706.75 lakh, repaid ₹391.15 lakh in FY2024

FY2023-24 AR

Revenue by Segment and Revenue by Segment (%)

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Consolidated revenue from operations

20.1112.0213.7815.6211.20

Standalone revenue from operations (software + real estate)

17.839.809.7112.188.06

Subsidiaries contribution derived (consolidated minus standalone, before eliminations)

2.282.224.073.443.14

Standalone share of consolidated revenue % derived

88.781.570.578.072.0

Standalone revenue YoY growth % derived

—-45.0-0.925.4-33.8

Revenue by Segment (x) and Results by Segment

Metric (INR Lakh)FY2024FY2025

Medley Medical turnover (AOC-1)

92.37—

Medley Medical revenue from operations (Directors' Report extract)

23.822.71

Medley Medical net profit (Directors' Report extract)

-374.86-301.71

Tutoroot turnover (AOC-1)

36.01—

Tutoroot PBT (AOC-1)

4.11—

Income Statement and Per-Share Data

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

20.1112.0213.7815.6211.20

Gross profit (S&P definition)

2.38-4.15-0.952.401.74

Total operating expenses (Screener)

2827332324

EBITDA excluding other income (Screener operating profit)

-8-15-19-7-13

Other income

91237125

Finance cost

97111217

Depreciation

01012

Exceptional items

0000-32.36

Profit before tax (reported)

-8-22.65205.82-19.23-38.73

Net profit (reported)

-8.07-22.03205.10-20.14-45.68

EPS basic ₹ (reported)

-5.80-15.65146.19-14.16—

EPS ₹ derived on about 14.5m weighted shares

————-31.5

Dividend per share ₹

00000

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Gross margin derived

11.8-34.5-6.915.415.5

EBITDA margin excluding other income (Screener OPM)

-38-127-140-46-115

Net margin derived

-40.1-183.31,488.4-128.9-407.9

Revenue growth YoY derived

-22.8-40.214.613.4-28.3

Income Statement

Metric (INR Cr)Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Sales

4.174.374.192.893.022.572.213.404.75

Operating profit

-2.17-0.85-0.03-4.19-1.39-3.56-6.72-1.17-0.04

Other income

0.030.180.010.450.020.3423.520.710.03

Interest

2.692.803.662.902.632.897.103.972.71

PBT

-4.90-3.50-3.84-6.99-4.35-6.509.32-37.20-3.13

Net profit (reported)

-4.74-4.69-3.84-6.88-4.34-6.371.14-36.11-3.15

Balance Sheet

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Total assets

7795325342312

Fixed assets incl. investment property

3938273282203

Capital work in progress

1925324042

Investments

06300

Other assets (incl. receivables and cash)

1926172066

Equity share capital

1313141415

Reserves

-5-24186166127

Total equity derived

8-11200180142

Total borrowings

457486100130

Other liabilities

2431396241

Cash Flow

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow (Screener)

-4-211213-57

Operating cash flow (Torus / reported variant)

-4.14-20.7511.809.61—

Investing cash flow

-9-13-5-448

Financing cash flow

1235-8-918

Free cash flow (Screener)

-13-2747-62

Dividends paid

00000

Buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE % (net profit / average equity)

——422.4-10.6-28.4

ROE % (Screener, last year)

————-27.7

ROA % (net profit / year-end total assets)

-10.5-23.263.1-5.9-14.6

ROCE % (Screener)

3-26124-3-5

ROIC % (S&P / MarketInOut, latest TTM)

————-3.52

Debt to equity (x)

5.63—0.430.560.92

Interest coverage (EBIT incl. other income / interest, x)

0.1-2.119.8-0.60.6

Asset turnover (revenue / total assets, x)

0.260.130.040.050.04

Debtor days (Screener)

1362376990202

Cash conversion cycle days (Screener)

70162-13390202

Income Statement (Annual)

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Standalone revenue from operations

17.839.809.7112.188.06

Standalone other income

9.201.75238.842.48—

Standalone PBT

—-9.56214.42-13.23—

Standalone net profit

—-8.90213.74-14.12-39.70

Results by Region

Metric (INR Lakh)FY2019FY2020FY2023FY2024

Foreign exchange earnings

820.331,292.57687.23817.70

Foreign exchange outgo

247.85441.59272.68272.75

Net FX earnings derived

572.48850.98414.55544.95

Revenue by Region (%)

Metric (%)FY2023FY2024

FX earnings as % of standalone revenue derived

70.184.2

Domestic share of standalone revenue derived

29.915.8

Valuation Snapshot

MetricValueSource

Last close

₹51.20 (19 Oct 2026)

Screener

52-week range

₹49.4 – ₹92.4

Screener

1-year return

-34%

Screener

3-year price CAGR

-13%

Screener

5-year price CAGR

-11%

Screener

10-year price CAGR

+3%

Screener

5-year high / low

₹129.89 / ₹30.00

HDFC Sky (Apr 2026)

Per-Share Data

Metric (₹ per share)FY2025FY2026

Book value per share consolidated derived (equity / shares)

12897

Valuation Multiples

MultipleAthena GlobalKellton TechSaksoftMindteck

P/E (TTM)

Not meaningful (TTM net loss about ₹44.5 Cr, derived)

60.2 (Screener snapshot; date of snapshot uncertain)

About 14 (derived: about ₹1,899 Cr market cap / ₹133 Cr PAT; snapshot date uncertain)

About 19.9 (Aug 2026)

P/B

0.51

3.11 (snapshot)

Not captured

Not captured

EV/EBITDA

Not meaningful (negative EBITDA)

Not captured

Not captured

Not captured

EV/Sales (TTM)

About 15.9x derived (EV about ₹205 Cr = ₹75 Cr market cap + ₹130 Cr gross debt, cash not deducted; TTM sales ₹12.93 Cr). MarketInOut shows 14.33x.

Not captured

Not captured

Not captured

Capital Markets

ItemStatusSource

Analyst consensus

None — 0 analysts cover the stock

S&P via Simply Wall St

Algorithmic ratings

Marketsmojo "Strong Sell" (Jun 2026)

Marketsmojo

Dividend history

No dividend ever declared

FY2023-24 AR

Dividend policy

Not disclosed beyond "inadequacy of profit"

AR

Moody's / S&P / Fitch

Not rated

—

Domestic rating

Infomerics rated the proposed ₹150 Cr NCDs (grade not captured); issue withdrawn

BSE / Infomerics

Lender identity

Not publicly disclosed beyond related-party loans (M. Satyendra, M. Sunitha, Vishwashree Enterprises)

FY2023-24 AR

Implied cost of debt

About 13% (FY2026 finance cost ₹17 Cr / borrowings ₹130 Cr, derived)

Screener

Analyst Conclusions

Management guidance and consensus

Management guidance: none quantified. The MD&A expresses generic confidence in winning new projects.

Consensus: none (no coverage).

Data-implied run-rate (analyst scenario, not guidance)

  • Software and other operating revenue at the Q1 FY2027 level: about ₹4.75 Cr per quarter, or about ₹19 Cr annualised.

  • Lease income: ₹11.19 Cr per year from 27 Nov 2026, or about ₹4 Cr in FY2027 and a full ₹11.19 Cr from FY2028.

  • If operating costs stay near Q1 FY2027 levels (about ₹4.8 Cr per quarter) and finance cost stays at about ₹11–17 Cr, FY2028 could be near PBT break-even. That outcome assumes no further subsidiary losses or write-downs.

Bull case

  1. The lease transforms the revenue mix. ₹11.19 Cr of annual contracted rent from 27 Nov 2026, on a 5-year tenor, roughly doubles recurring revenue against FY2026's ₹11.2 Cr. Rental income carries high margins.

  2. Deep asset discount with a visible catalyst path. P/B is about 0.5x. Further leasing or sale of the remaining approved inventory, in a Hyderabad market absorbing a record 13+ mn sq ft in nine months, could crystallise value and reduce the ₹130 Cr of debt.

  3. The operating cost base has been reset. Q1 FY2027 OPM of -0.84% is the best in the visible quarterly series. Sales grew 57% YoY. The promoter keeps injecting equity at ₹84–87, a price above the current ₹51.

Bear case

  1. Leverage exceeds operating capacity. Interest of ₹17 Cr against ₹11 Cr of revenue, debt up ₹44 Cr in two years, and a failed NCD raise. Lease cash may service debt rather than create equity value.

  2. Capital allocation has repeatedly destroyed value, and may again. Medley's ₹33.6 Cr investment was sold intra-group for ₹1.25 Cr. The new ₹50 Cr OCD approval targets the same subsidiaries. Equity fell from ₹200 Cr to ₹142 Cr in two years.

  3. Governance and disclosure quality are weak. Related-party loans and sale, CMD duality, short independent director terms, AR inconsistencies, no investor communication, and zero institutional ownership. All of this justifies a structural discount that may not close.

Catalysts and monitorables (next 12 months)

#ItemTimingWhat to watch
1Q2 FY2027 resultsAbout mid-Nov 2026Whether Q1's near-break-even operating profit holds; finance cost trend
2Lease commencement27 Nov 2026Rent recognition in Q3/Q4 FY2027; lessee identity and security deposit
3OCD deploymentAny timeAmount actually invested in Medley / Tutoroot out of the ₹50 Cr approved; terms and coupon
4DebtQuarterlyAny refinancing, repayment, or lender disclosure; trend in the ₹130 Cr borrowings
5Warrant conversionBy about Oct 2027 (18-month SEBI limit, derived)Conversion of 7 lakh warrants (balance about ₹4.41 Cr, derived) — a signal of promoter conviction
6Remaining property inventoryFY2027Further leases or sales out of the 1.5 lakh sq ft approved in Feb 2025
7MD re-appointment / governanceFY2027MD term expired 13 May 2026 — confirm re-appointment and any independent director refresh
8FY2026 AR detailsAvailableSegment results, debt maturities, lessee/receivable disclosures, auditor opinion type
9Q4 FY2027 / FY2027 resultsMay 2027First full-quarter rent; any fair-value movements on the property

Concluding analyst verdict

Athena Global Technologies should not be analysed as the IT services company its name suggests. Over five years:

  • Consolidated operating revenue has roughly halved, to ₹11.2 Cr.

  • Operating losses have been continuous.

  • The headline profits of FY2024 (₹205 Cr) and Q3 FY2026 (₹1.14 Cr) were produced by non-cash fair-value and derecognition gains on a single real estate asset in Hyderabad's Financial District.

That asset is the company. It supports roughly ₹203 Cr of fixed assets, the ₹142 Cr equity base, and the ₹130 Cr of high-cost debt.

The September 2026 lease of 1,19,526 sq ft at ₹11.19 Cr a year is the most important positive development in the company's recent history. It arrives during an exceptional Hyderabad leasing cycle. Q1 FY2027 also offered the first evidence that the operating cost base has been reset. Together these make a path to near-break-even plausible within about 18 months, and the stock's 0.5x price-to-book discount gives room for re-rating if that path is executed.

Against this, minority shareholders face three structural problems:

  • Leverage is large relative to cash generation.

  • Capital allocation has repeatedly favoured promoter-incubated subsidiaries at shareholders' expense, most recently through a related-party Medley transfer at a ₹32 Cr loss and a fresh ₹50 Cr OCD approval.

  • Governance and disclosure standards are well below institutional norms: no analyst coverage, no investor calls, inconsistent AR disclosures and no institutional shareholders.

Verdict. This is a speculative, special-situation real estate monetisation story with high governance risk. The decisive monitorables over the next two to four quarters are:

  • Lease cash actually reaching the P&L from Q3 FY2027.

  • Debt reduction rather than OCD deployment.

  • Conversion of the outstanding promoter warrants.

Absent clear progress on all three, the discount to book is likely to persist or widen.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundEducationSource

M. Satyendra (Satish Manchala)

Chairman & Managing Director (DIN 01843557); promoter

—

3+ decades in industry; leads international operations; founder of MedleyMed and Tutoroot

Management graduate

FY2023-24 AR

Sudeep Nadkarni

Chief Executive Officer

Since 1 Aug 2023 (per MarketScreener)

Chief Revenue Officer (GBR) at 3i Infotech (Nov 2022–2023); earlier at Kanbay Inc. (business intelligence lead); also listed by S&P as CEO of ALTAFID Inc.

MBA, Kellogg School of Management

MarketScreener; Simply Wall St

Julakanti Venkata Ramakrishna

Chief Financial Officer

About 6 years (S&P)

——

FY2023-24 AR; Simply Wall St

Divya Agrawal

Company Secretary & Compliance Officer (FY2022–FY2024 filings)

Through at least FY2024

Membership No. 48143

CS

BSE filings

Gayathri Prithviraj

Company Secretary & Compliance Officer (per S&P, under 1 year)

2025–26

—

CS

Simply Wall St

Rajesh Patil

Chief Operating Officer

———

Simply Wall St

Abdul Ghalib

Senior Vice President

———

Simply Wall St

Phaniraj Uppendra Gollapudi

SVP, Engineering Services

———

Simply Wall St

“—” = not publicly disclosed.

Board of Directors

NameCategoryAppointedCommitteesNotes

M. Satyendra

Promoter, Chairman & MD (executive)

Inception

—

Spouse of M. Sunitha

M. Sunitha (Sunitha Manchala)

Non-executive, promoter, woman director (DIN 06741426)

6 Nov 2014

—

Born 6 Sep 1974; B.A., B.Com, LLB; finance and administration expertise; holds 16,41,326 shares; re-appointed at the 34th AGM (30 Sep 2026)

Avinash Vashistha

Non-executive director

—

Audit / NRC / SRC member until 14 Nov 2023

Classified as "Director" in corporate information but "Non-Executive Independent Director" in the governance table — internal inconsistency. Holds 2,00,000 shares; Vashistha family members (Garima 2.61%, Ankita 1.21%) also hold stakes.

Ramesh Babu Nemani

Independent director

—

Chairman of Audit, NRC and SRC from 8 May 2023

—

Nukala Ashwanth

Independent director (DIN 09719259)

1 Sep 2022; re-appointed for 1 year from the 32nd AGM (Sep 2024)

Member of all 3 committees

Born 27 Jul 1988

Maddi Venkata Sudarsan

Independent director (DIN 00988521)

2 Aug 2023 for 2 years

Member of all 3 committees from 14 Nov 2023

—

Prudvi Raju Manthena

Independent director (former)

—

Former Audit Committee Chair

Died 6 May 2023

“—” = not publicly disclosed.

Executive Leadership Team — M. Satyendra

NameRoleSalary / remuneration (INR Lakh)StockTotal (INR Lakh)

M. Satyendra

CMD

58.40

Nil disclosed

58.40

J.V. Ramakrishna

CFO

11.54

ESOP eligibility not disclosed

11.54

Divya Agrawal

CS

10.66—10.66

Major Shareholders

HolderCategoryShares% of 1,47,00,000Source

M. Satyendra

Promoter

69,90,612

47.52

Bajaj Finserv (BSE shareholding)

Sunitha Manchala

Promoter

16,41,326

11.16

Same

Karthikeya Manchala

Promoter group

6,50,000 (+7,00,000 warrants)

4.42

Same; BSE

Garima Vashistha

Public

3,83,413

2.61

Same

Vijay Acharya

Public

2,39,079

1.63

Same

Aluri Srinivasa Rao

Public

2,17,684

1.48

Same

Avinash Vashistha

Public (director)

2,00,000

1.36

Same

Ankita Vashistha

Public

1,78,228

1.21

Same

Vipul Premchand

Public

1,74,911

1.19

Same

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning vs Athena

Software services / digital transformation

Kellton Tech Solutions (Hyderabad)

Listed small-cap

About 100x Athena's revenue; profitable; same city and similar digital/AI pitch

Software services

Saksoft

Listed small-cap

₹1,007 Cr revenue, about 20% EBITDA margin; US/UK mid-market focus

Software / engineering services

Mindteck (India)

Listed micro/small-cap

₹407 Cr revenue; profitable; niche engineering verticals

QA & testing

Cigniti Technologies (Hyderabad; now part of the Coforge group)

Listed specialist

Global QA leader among Indian mid-tiers; Athena's QA offering is sub-scale by comparison

IT services (micro-cap peers)

AAA Technologies, Sylph Technologies

Listed micro-caps

Comparable scale; listed by Simply Wall St in the same peer screens

Offshore development (private)

NeoSOFT Technologies, Alphamu Software, Empiezo IT Solutions

Private

Named by CB Insights as Athena competitors

IT services (large)

Tech Mahindra, EXL, Quantiphi

Large / mid

Named as competitors by TheCompanyCheck; not realistic head-to-head peers

Online education

PhysicsWallah, Vedantu, BYJU'S, Unacademy

Ed-tech platforms

Orders of magnitude larger; Tutoroot is sub-scale

E-pharmacy / pharmacy SaaS

Tata 1mg, PharmEasy (API Holdings), Apollo 24/7, Netmeds

Platforms

MedleyMed is sub-scale; healthcare exit effectively executed Mar 2026

Hyderabad office real estate

RMZ, Salarpuria Sattva, Phoenix Group, office REITs with Hyderabad assets

Developers / landlords

Athena is a single-asset landlord and price-taker in a deep market

Peer Comparison FY2026

MetricAthena GlobalKellton TechSaksoftMindteck

Revenue (INR Cr)

11.20

1225.36 (total revenue)

1,007.19407.30

Revenue growth YoY %

-28.311.414-4.0

Operating / EBITDA margin % (excluding other income)

-115

Not captured

20.59.3

Net profit (INR Cr)

-45.6891.66133.2731.52

Net margin %

-407.97.513.27.7

Company Snapshot

$1.3M

Revenue

65

Employees

1991

Founded

Hyderabad, India

Headquarters

SWOT Analysis

Strengths

  • Hard-asset backing. Investment property was fair-valued at ₹239 Cr in FY2024; fixed assets were still ₹203 Cr at Mar 2026 after a partial disposal (Screener).
  • Contracted recurring income. A 5-year lease of 1,19,526 sq ft at ₹11.19 Cr per year from 27 Nov 2026 (BSE, 18 Sep 2026) roughly equals FY2026 consolidated revenue of ₹11.2 Cr.
  • Promoter commitment. Three warrant issues to promoters: ₹59 (converted Nov 2023), ₹87 (converted Aug 2025) and ₹84 (allotted Apr 2026). Promoter stake rose from 47.38% (FY2017) to 63.09% (FY2026).
  • Deep discount to book. P/B of about 0.51x (₹51.2 price vs ₹101 book value, Screener 19 Oct 2026).
  • Cost reset visible. Q1 FY2027 operating margin was -0.84% vs -46.03% in Q1 FY2026, with sales +57% YoY (Capital Market, 15 Aug 2026).
  • Export-oriented services. 84% of FY2024 standalone revenue was foreign-exchange earnings (₹817.70 lakh of ₹970.95 lakh, FY2023-24 AR), giving a natural USD hedge.

Weaknesses

  • Shrinking core revenue. Consolidated revenue fell from ₹26 Cr (FY2020–21) to ₹11.2 Cr (FY2026); 5-year sales CAGR is -16% (Screener).
  • Chronic operating losses. EBITDA excluding other income was negative in each of FY2022–FY2026 (-8, -15, -19, -7, -13 ₹ Cr).
  • Leverage and finance cost. Borrowings rose from ₹45 Cr (FY2022) to ₹130 Cr (FY2026); finance cost of ₹17 Cr in FY2026 exceeded revenue.
  • Value-destructive subsidiaries. Medley investment of ₹3,360.94 lakh (FY2022 AR) was sold for ₹125.34 lakh, crystallising a ₹32.36 Cr exceptional loss in FY2026.
  • Earnings quality. About ₹261 Cr of cumulative FY2022–FY2026 other income, mostly non-cash fair-value or derecognition gains, masks the operating picture. Screener notes earnings include large other income.
  • Governance gaps. CMD combines chair and executive roles; independent directors serve 1–2 year terms; identical membership across all committees; AR inconsistencies (10 vs 9 board meetings; Vashistha classified two ways).

Opportunities

  • Hyderabad leasing boom. Record 13.1–13.2 mn sq ft absorbed in Jan–Sep 2026 (Knight Frank) supports leasing the remaining inventory beyond the 1.20 lakh sq ft already contracted (out of 1.5 lakh sq ft approved for sale or lease in Feb 2025).
  • Deleveraging. Applying lease cash flows or asset-sale proceeds to the ₹130 Cr of high-cost debt could swing interest cost (₹17 Cr) toward break-even.
  • AI services re-positioning. The website rebrand ("Custom AI Solutions & Automation Services") and the CEO's 3i Infotech revenue background could revive US services.
  • Small base effect. Q1 FY2027 sales of ₹4.75 Cr annualise to about ₹19 Cr (derived). Combined with about ₹11 Cr of rent, FY2028 revenue could exceed ₹30 Cr if sustained (scenario, not guidance).
  • Re-rating from P/B 0.5x. Re-rating is possible if losses stop. Comparable profitable micro-caps trade above book.
  • UK subsidiary. Incorporated May 2024; offers optional entry into the UK mid-market (Saksoft derived 29% of FY2026 revenue from Europe, per MNCL).

Threats

  • Capital diversion. The approved ₹50 Cr OCD investment in Medley Medical and Tutoroot (May 2026) could absorb monetisation proceeds and repeat past subsidiary losses.
  • Related-party exposure. Promoter loans received of ₹358.33 lakh (FY2024), Vishwashree Enterprises loans of ₹706.75 lakh, and a Medley sale to a related party all raise minority-protection risk.
  • Lessee concentration. A single 5-year lease; counterparty identity and credit quality are not captured in sources reviewed.
  • Refinancing risk. The withdrawn ₹150 Cr NCD (Feb 2025) shows limited access to market debt. Infomerics flagged negative cash accruals (about -₹13.18 Cr) against about ₹11 Cr of interest.
  • IT services demand softness. Peers saw subdued growth in Q1 FY2027 (Saksoft PAT -9.4% YoY; Mindteck PAT -4.5% YoY).
  • Liquidity and delisting-type risks for minorities. No institutional holders, 7,867 shareholders, low traded volumes (for example, 1,596 shares on 18 Jul 2026, Torus), and further warrant dilution.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
25 Feb 2025₹150 Cr NCD issue withdrawn; sale/lease of 1,50,000 sq ft approved Reuters / ZerodhaPivot from debt refinancing to asset monetisation
30 May 2025 (approx.)FY2025 results: consolidated loss ₹20.14 Cr; standalone loss ₹14.12 Cr FY2024-25 Directors' ReportReturn to losses after the FY2024 fair-value year
Jun 2025Q4 FY2025 net loss ₹6.88 Cr ScreenerWeak exit rate
Jul 2025Reg. 74(5) compliance certificate FinologyRoutine
11 Aug 2025Q1 FY2026 results: net loss ₹4.34 Cr on sales of ₹3.02 Cr; 6.5 lakh warrants converted at ₹87 Screener; Capital MarketPromoter equity infusion; stake to 63.09%
11 Sep 2025Notice of 33rd AGM ScreenerGovernance
30 Sep 202533rd AGM ScreenerGovernance
14 Nov 2025Q2 FY2026: net loss ₹6.37 Cr; sales -41% YoY to ₹2.57 Cr; OPM -138.5% Business StandardDeterioration in software revenue
4 Dec 2025Board outcomes (three filings) and notice of postal ballot FinologyLikely capital or corporate actions; details not captured
31 Dec 2025Trading window closure FinologyRoutine
12–14 Feb 2026Q3 FY2026: standalone profit ₹348.36 lakh; consolidated PAT ₹1.14 Cr driven by ₹23.52 Cr other income (property derecognition gain ₹23.40 Cr); sales -47% YoY to ₹2.21 Cr ScanX; Moneycontrol via CB InsightsPaper profit; core business still shrinking
Feb 2026Board considers fund-raising proposal alongside Q3 results ScanXFunding need
20 Mar 2026Corrigendum to EGM notice FinologyProcedural
25 Mar 2026EGM approves 7 lakh warrants at ₹84 to Karthikeya Manchala ScanXPromoter support
31 Mar 2026Acquisition of MedleyMed Healthcare (₹10,000) and divestment of Medley Medical (₹1.25 Cr) IndiaIPO; WhalesbookRelated-party restructuring; triggers ₹32.36 Cr loss
1 Apr 2026BSE in-principle approval for warrants ScanXProcedural
13 Apr 20267 lakh warrants allotted; ₹1.47 Cr received; shares fall 2.89% to ₹63.12 HDFC SkyDilution concern
30 May 2026FY2026 audited results: consolidated loss ₹45.68 Cr, standalone loss ₹39.70 Cr; ₹32.36 Cr exceptional loss; ₹50 Cr OCD investment approved Whalesbook; ScanXMajor capital-allocation decision
1–2 Jun 2026Q4 FY2026 loss of ₹36.11 Cr; employee cost 82.65% of revenue (Marketsmojo); "Strong Sell" rating by Marketsmojo's algorithmic model Marketsmojo; Kotak NeoSentiment negative
Jul 2026Stock trades about ₹54–62; 1-year return about -33% IIFL; TorusWeak market reception
15 Aug 2026Q1 FY2027: sales +57% YoY to ₹4.75 Cr; net loss narrows to ₹3.15 Cr; OPM -0.84% Capital Market / JM FinancialFirst sign of operating stabilisation
3 Aug 2026Stock up 5% to ₹59.85 (upper circuit) Choice IndiaVolatility
18 Sep 20261,19,526 sq ft leased for 5 years at ₹11.19 Cr per year from 27 Nov 2026 BSE / ScreenerTransformational to the revenue base
23 Sep 2026Stock at ₹53.25; 1-year return -42.7% Anand RathiMarket not yet pricing the lease
28 Sep 2026Trading window closed from 1 Oct 2026 until 48 hours after Q2 results ScreenerQ2 FY2027 results due about mid-Nov 2026
30 Sep 202634th AGM by VC: FY2026 accounts adopted; M. Sunitha re-appointed ScreenerGovernance
1 Oct 2026Scrutiniser's report: all AGM resolutions passed ScreenerGovernance
7 Oct 2026Reg. 74(5) certificate for Q2 FY2027 ScreenerRoutine
19 Oct 2026Stock closes at ₹51.20 (-6.07% on the day), near its 52-week low of ₹49.4 ScreenerMarket cap about ₹72–75 Cr

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 201.1 Mn in FY2022 to INR 112 Mn in FY2026.
Athena Global Technologies Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations201.1120.2137.8156.2112
Gross profit (S&P definition)23.8-41.5-9.52417.4
Standalone revenue from operations178.39897.1121.880.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. 1Annual Report FY2023-24 (32nd), — Board, KMP, auditors, financial highlights, investment property, segments, AOC-1, AOC-2, remuneration, FX earnings (athenagt.com)
  2. 2Annual Report FY2021-22 (30th), and — FY2022 revenue, subsidiary investments: athenagt.com · bseindia.com
  3. 3Annual Report FY2019-20 (28th), — FX earnings FY2019–20 (athenagt.com)
  4. 4Directors' Report FY2024-25 (33rd) via and goodreturns.in — FY2025 financial highlights (indiainfoline.com)
  5. 5BSE filing — Outcome of Board Meeting 30 May 2024 (72cdebfd…; 4a7691a6…) — FY2024 results, ESOP
  6. 6BSE filing — UK WOS incorporation 30 May 2024 (2a4f3ef0…) — UK subsidiary
  7. 7BSE filing — Board outcome 12 Feb 2024 (d4aae1f2…) — Warrant allotment
  8. 8BSE filing — Infomerics NCD rating (54112083…) — Debt of ₹85.39 Cr, NCD purpose
  9. 9BSE filing — Board outcome 1 Sep 2022 (44c0d07c…) — Independent director appointment
  10. 10Screener.in consolidated page ( accessed 20 Oct 2026 — P&L, balance sheet, cash flow, ratios, quarterly data, shareholding, announcements, price (screener.in)
  11. 11StockAnalysis.com ( — Gross profit, FY2026 net income (stockanalysis.com)
  12. 12Business Standard / Capital Market (Q4 FY2024, Q2 FY2026 results) — Quarterly and annual results
  13. 13JM Financial / Capital Market news, 15 Aug 2026 — Q1 FY2027 results
  14. 14Whalesbook (30–31 May 2026; 31 Mar 2026) — FY2026 results, exceptional items, OCD, Medley transactions
  15. 15IndiaIPO news (Mar 2026) — MedleyMed transaction details
  16. 16ScanX (FY2026 loss; warrant allotment; Q3 FY2026) — FY2026 standalone, warrants, Q3
  17. 17Marketsmojo (Jun 2026) — Q4 FY2026 analysis, employee cost ratio
  18. 18Kotak Neo (Q4 FY2026) — Q4 FY2026 figures
  19. 19HDFC Sky (13 Apr 2026; Apr 2026 price data) — Warrant issue, price history
  20. 20Reuters via Zerodha — NCD withdrawal, sale/lease approval
  21. 21Equity Bulls (31 May 2024; 20 Aug 2024) — FY2024 EPS, NCD approval
  22. 22Simply Wall St (S&P Global Market Intelligence) — Employees, CEO, management, description
  23. 23MarketScreener — CEO start date, education
  24. 24Bajaj Finserv, Upstox, IIFL, Emkay, Choice India, Pocketful — Shareholding
  25. 25IIFL / Capitaline company summary — Corporate history
  26. 26TheCompanyCheck (MCA data) — CIN history, auditor, FY2026 revenue
  27. 27LinkedIn company pages; Craft.co; Justdial — Office locations
  28. 28BioSpectrum India; Indian PharmaPost; Business India; YourStory — MedleyMed history and offerings
  29. 29Business News Today; Glassdoor — Tutoroot
  30. 30Infyner (MCA) — Medley incorporation
  31. 31MarketInOut (Sep 2026) — ROIC, EV/Revenue, F-score, M-score
  32. 32Knight Frank via NewsMeter / Urban Acres (Oct 2026) — Hyderabad office leasing
  33. 33FilingReader (Kellton FY2026); Anand Rathi & MNCL (Saksoft FY2026); Anand Rathi & Marketsmojo (Mindteck FY2026) — Peer benchmarking
  34. 34ICICIdirect, Business Standard, Anand Rathi, Torus Digital, IIFL — Historical price points
  35. 35CB Insights; Finology Ticker — Competitor names; filing headlines

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.